Antifungal Resistance and Novel Mycology Diagnostics

Clinical Center

Investigators

Linked publications & trials

Abstract

Invasive and life-threatening fungal infections represent one of the most pressing challenges in modern medicine, particularly in vulnerable patient populations. These infections are notoriously difficult to manage in individuals who are immunocompromised, such as those undergoing chemotherapy for hematologic malignancies like acute myelogenous leukemia, or in patients hospitalized with severe underlying diseases. They also occur frequently in individuals who undergo complex surgical procedures, such as those performed in cases of severe trauma, and in critically ill patients requiring prolonged stays in intensive care units. In these settings, the immune system is often weakened, and invasive fungal pathogens can take advantage of this compromised state, leading to devastating outcomes. Despite a steady increase in the incidence of fungal infections over the past several decades, the therapeutic arsenal available to clinicians remains limited. Currently, only a handful of antifungal drug classes exist, and these agents often display restricted efficacy, particularly when used against invasive fungal infections. The challenge is further exacerbated by the emergence and spread of antifungal resistance in several major fungal pathogens, such as Candida and Aspergillus species. Resistance diminishes the effectiveness of standard treatment regimens, leaving physicians with few viable options and forcing them to rely on drugs that may be less effective, more toxic, or both. This resistance crisis is directly associated with unacceptably high morbidity and mortality rates, underscoring the urgent need for innovative therapeutic solutions. For this reason, one of the central aims of my research is to investigate the prevalence of antifungal resistance among patients hospitalized at the NIH. By mapping resistance patterns, we can gain a clearer understanding of the scope of the problem and inform more effective treatment strategies. In parallel, my work also seeks to evaluate the efficacy of novel investigational systemic antifungal drugs, with particular emphasis on those agents that show activity against difficult-to-treat molds and yeasts. Such efforts are essential to expand the therapeutic pipeline and address current gaps in antifungal care. Equally critical to improving patient outcomes is the timely and accurate diagnosis of invasive fungal diseases. Unfortunately, diagnosis in this field remains fraught with challenges. Traditional diagnostic methods often lack sensitivity and specificity, and in many cases, they require prolonged time to generate results. Such delays can render them of limited clinical utility, as early intervention is key to improving survival rates. A single diagnostic technology is unlikely to solve these problems in isolation. Instead, a comprehensive diagnostic strategy must integrate multiple complementary approaches. These include advanced techniques such as MALDI-TOF mass spectrometry for species-level identification, the use of fungal biomarkers, antigen and antibody-based assays, and nucleic acid amplification tests that can detect fungal DNA directly from patient samples. By leveraging the strengths of each of these tools and integrating them into optimized testing algorithms, we can improve both the speed and accuracy of diagnosis. The second major focus of my research will therefore be on developing strategies and approaches to enhance fungal detection and identification. This involves not only refining existing technologies but also working toward methodologies that allow for rapid and reliable identification of fungi at the species level, even directly from complex clinical samples. Such advances will be invaluable in diagnosing emerging and rare fungal infections, which are often overlooked or misclassified by current diagnostic methods. Ultimately, improving diagnostics alongside expanding therapeutic options has the potential to significantly advance the field, reduce mortality, and provide critically ill patients with a greater chance of survival.